Yesterday, March 16, 2016, 100 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $51.12 to $7,757,838.42.

Highlighted Stocks Traded by Insiders:

Masco (MAS) - FREE Research Report

Manoogian Richard A, who is Director at Masco, sold 40,000 shares at $29.57 on March 16, 2016. Following this transaction, the Director owned 514,611 shares meaning that the stake was reduced by 7.21% with the 40,000-share transaction.

The shares most recently traded at $30.54, up $0.97, or 3.19% since the insider transaction. Historical insider transactions for Masco go as follows:

  • 4-Week # shares bought: 3,000
  • 4-Week # shares sold: 260,000
  • 12-Week # shares bought: 3,000
  • 12-Week # shares sold: 260,000
  • 24-Week # shares bought: 3,000
  • 24-Week # shares sold: 564,800

The average volume for Masco has been 5.1 million shares per day over the past 30 days. Masco has a market cap of $10.0 billion and is part of the industrial goods sector and materials & construction industry. Shares are up 5.94% year-to-date as of the close of trading on Wednesday.

Masco Corporation designs, manufactures, markets, and distributes home improvement and building products in North America and internationally. The stock currently has a dividend yield of 1.27%. The company has a P/E ratio of 28.9. Currently, there are 9 analysts who rate Masco a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MAS - FREE

TheStreet Quant Ratings

rates Masco as a

hold

. The company's strengths can be seen in multiple areas, such as its solid stock price performance and revenue growth. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, weak operating cash flow and poor profit margins. Get the full

Masco Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Sarepta Therapeutics (SRPT) - FREE Research Report

Price Ben Gil, who is Director at Sarepta Therapeutics, bought 4,500 shares at $16.70 on March 16, 2016. Following this transaction, the Director owned 42,830 shares meaning that the stake was boosted by 11.74% with the 4,500-share transaction.

Barry Richard, who is Director at Sarepta Therapeutics, bought 75,000 shares at $15.66 on March 16, 2016. Following this transaction, the Director owned 3.2 million shares meaning that the stake was boosted by 2.37% with the 75,000-share transaction.

The shares most recently traded at $16.45, up $0.79, or 4.83% since the insider transaction. Historical insider transactions for Sarepta Therapeutics go as follows:

  • 4-Week # shares bought: 1,600
  • 4-Week # shares sold: 15,933
  • 12-Week # shares bought: 1,600
  • 12-Week # shares sold: 15,933
  • 24-Week # shares bought: 1,600
  • 24-Week # shares sold: 15,933

The average volume for Sarepta Therapeutics has been 1.9 million shares per day over the past 30 days. Sarepta Therapeutics has a market cap of $692.3 million and is part of the health care sector and drugs industry. Shares are down 62.29% year-to-date as of the close of trading on Wednesday.

Sarepta Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery and development of RNA-based therapeutics for the treatment of rare, infectious, and other diseases. Currently, there are 6 analysts who rate Sarepta Therapeutics a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SRPT - FREE

TheStreet Quant Ratings

rates Sarepta Therapeutics as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share. Get the full

Sarepta Therapeutics Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Colfax (CFX) - FREE Research Report

Vinnakota Rajiv, who is Director at Colfax, sold 2,038 shares at $27.31 on March 16, 2016. Following this transaction, the Director owned 16,719 shares meaning that the stake was reduced by 10.87% with the 2,038-share transaction.

The shares most recently traded at $29.12, up $1.81, or 6.22% since the insider transaction. Historical insider transactions for Colfax go as follows:

  • 4-Week # shares bought: 10,100
  • 4-Week # shares sold: 5,389
  • 12-Week # shares bought: 10,100
  • 12-Week # shares sold: 22,445
  • 24-Week # shares bought: 10,100
  • 24-Week # shares sold: 23,825

The average volume for Colfax has been 1.3 million shares per day over the past 30 days. Colfax has a market cap of $3.4 billion and is part of the industrial goods sector and industrial industry. Shares are up 21.5% year-to-date as of the close of trading on Wednesday.

Colfax Corporation, an industrial manufacturing and engineering company, provides gas- and fluid-handling, and fabrication technology products and services worldwide. The company operates in two segments, Gas- and Fluid-Handling, and Fabrication Technology. The company has a P/E ratio of 20.5. Currently, there are 4 analysts who rate Colfax a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CFX - FREE

TheStreet Quant Ratings

rates Colfax as a

hold

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and expanding profit margins. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and a generally disappointing performance in the stock itself. Get the full

Colfax Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.